[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prognosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prognosis":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,44,72,100,129,155,181,211,244,273,295,321,341,371,406,432,455,491,513,540,566,592,615,637],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641646","molecular-subtype-guided-postoperative-radiotherapy-for-phyllodes-tumor-of-the-breast-a-randomized-controlled-trial-100641646",false,"NCT07657169","Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast: A Randomized Controlled Trial","Efficacy and Safety of Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast: A Prospective, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Female patients aged ≥18 years and ≤75 years.\n2. Histologically confirmed breast phyllodes tumor (PT) by the central laboratory, with molecular classification as MN1 or MN2 subtype via transcriptome sequencing or IHC;\n3. Primary or ipsilateral local recurrence following R0 resection (negative margins) before enrollment;\n4. Pathologically confirmed borderline or malignant PT;\n5. No evidence of distant metastasis (M0);\n6. ECOG performance status 0-1;\n7. Signed informed consent before treatment;\n8. Expected randomization and study entry within 8-12 weeks (no later than 16 weeks) after surgery.\n\nExclusion Criteria:\n\n1. Previous radiation to the same-side breast or chest;\n2. women, or those of childbearing potential refusing effective contraception; Pregnancy, lactation, or refusal of contraception by fertile subjects;\n3. Grade III-IV bone marrow suppression: WBC≤1.9\\*109\u002FL，ANC≤0.9\\*109\u002FL，PLT≤49\\*109\u002FL，AST, ALT≥2\\*ULN;\n4. Significant diarrhea, severe active infection, uncontrolled systemic disease, interstitial lung disease, active connective tissue disease, or LVEF \\\u003C 50%;\n5. Significant diarrhea, severe active infection, uncontrolled systemic disease, interstitial lung disease, active connective tissue disease, or LVEF \\\u003C 50%;\n6. Prior or planned systemic anti-tumor therapy (chemotherapy, targeted therapy, immunotherapy, or investigational agents) during the study;\n7. Participation in other clinical trials that precludes study inclusion;\n8. Any other condition that, in the opinion of the investigator, renders the patient unsuitable for the trial.","FEMALE","18 Years","75 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","Phyllodes tumor (PT) of the breast is a rare fibroepithelial neoplasm, and the role of postoperative radiotherapy (PORT) remains controversial. Our team has previously established a molecular subtyping system for PT, classifying patients into four subtypes. Among them, the malignant novel 1\u002F2 (MN1\u002FMN2) subtypes exhibit extremely high risk of local recurrence, and retrospective data suggest that PORT may significantly improve local control in these subtypes. This study aims to evaluate the efficacy and safety of molecular subtype-guided postoperative radiotherapy (PORT) in patients with MN-subtype phyllodes tumor of the breast. This prospective, multicenter, open-label, randomized controlled trial plans to enroll 160 patients with molecularly confirmed MN1 or MN2 subtype who have undergone R0 resection. Patients will be randomized in a 1:1 ratio to either the PORT group or the observation-only group, with stratification by negative margin width (\\\u003C1 cm vs. ≥1 cm) and molecular subtype (MN1 vs. MN2). The primary endpoint is 2-year local recurrence-free survival (LRFS). Secondary endpoints include distant metastasis-free survival (DMFS), disease-free survival (DFS), overall survival (OS), and the incidence of acute and late radiotherapy-related toxicities. By using an innovative molecular subtyping system to precisely select the target population, this study seeks to assess the benefit and safety of PORT in MN-subtype phyllodes tumors. The results are expected to provide the highest level of evidence for this specific subgroup, advance treatment strategies toward \"molecular subtype-guided precision radiotherapy,\" improve patient outcomes, and inform future clinical guidelines.",[27,28,29,30],"Radiotherapy, Adjuvant","Phyllodes Breast Tumor","Prognosis","Molecular Typing","NOT_YET_RECRUITING","2026-06-15",{"date":34,"type":35},"2026-06-18","ACTUAL",{"date":37,"type":21},"2026-06-01",{"date":39,"type":21},"2030-12-31",{"name":41,"class":42},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100637724","dynamic-trajectories-of-pupillary-light-reflex-parameters-and-prognosis-in-critically-ill-patients-a-multicenter-prospective-cohort-study-100637724","NCT07616518","Dynamic Trajectories of Pupillary Light Reflex Parameters and Prognosis in Critically Ill Patients: A Multicenter Prospective Cohort Study","PUPIL","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Admission to the emergency intensive care unit.\n3. Critically ill patients with an expected EICU stay longer than 48 hours.\n4. Written informed consent obtained from the participant or legally authorized representative.\n\nExclusion Criteria:\n\n1. Severe ocular disease, severe ocular trauma, postoperative ocular status, or other conditions that prevent reliable pupillary measurement.\n2. Known neuro-ophthalmic disorders that may affect the pupillary light reflex, such as oculomotor nerve palsy.\n3. Use of topical ophthalmic medications during the study period that may significantly affect pupillary response, when their effects cannot be accurately recorded or evaluated.\n4. Pregnancy or breastfeeding.","ALL",{"count":53,"type":21},700,"OBSERVATIONAL","This multicenter prospective observational cohort study aims to investigate the association between early dynamic trajectories of pupillary light reflex parameters and clinical outcomes in critically ill patients admitted to emergency intensive care units. Quantitative pupillometry will be performed during the first 7 days after EICU admission. Constriction velocity will be the primary parameter for trajectory analysis, while dilation velocity, pupil diameter, constriction percentage, maximum constriction velocity, and latency will be analyzed as supplementary parameters. The study will evaluate whether these dynamic pupillary trajectories are associated with discharge outcome and 90-day functional outcome assessed by the Glasgow Outcome Scale-Extended.",[57,58,29],"Critical Illness","Pupillometry",[60,61,62,29,63],"Pupillary light reflex","Critically ill patients","Dynamic trajectory","Constriction Velocity","2026-05-24",{"date":37,"type":35},{"date":67,"type":21},"2026-06-06",{"date":69,"type":21},"2026-10-13",{"name":71,"class":42},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100640297","phase-2-spatiotemporal-evolution-of-traditional-chinese-medicine-mechanisms-in-acute-ischemic-stroke-treated-with-dengzhan-xixin-and-dengzhan-shengmai-100640297","NCT07591883","Spatiotemporal Evolution of Traditional Chinese Medicine Mechanisms in Acute Ischemic Stroke Treated With Dengzhan Xixin and Dengzhan Shengmai","STEM-DZ","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Meeting the diagnostic criteria for acute ischemic stroke in accordance with the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2023\n3. Within 48 hours after the first onset\n4. National Institutes of Health Stroke Scale (NIHSS) score ranging from 4 to 25 points\n5. Voluntarily signed informed consent.\n\nExclusion Criteria:\n\n1. Pre-stroke modified Rankin Scale (mRS) score ≥ 2\n2. Patients with transient ischemic attack (TIA), complicated with cerebral hemorrhage or subarachnoid hemorrhage\n3. patients with brain tumor, Alzheimer's disease, psychosis, or a confirmed diagnosis of dementia\n4. Patients undergoing endovascular thrombectomy\n5. Patients with severe cardiac diseases such as valvular heart disease, infective endocarditis, myocardial infarction, heart failure, severe hepatic or renal insufficiency, respiratory failure, malignant tumor, or massive gastrointestinal hemorrhage\n6. Patients who have used any preparations containing the same ingredients as the study drug (e.g., Erigeron breviscapus, ginseng, dwarf lilyturf tuber, schisandra chinensis, etc.) within the past 2 weeks\n7. Patients with a history of allergy to the study drug or preparations containing the same ingredients\n8. Pregnant or lactating women\n9. Patients judged by the investigators as unsuitable for participation in this trial.",{"count":80,"type":21},358,[82,83],"PHASE2","PHASE3","To integrate large-scale RCT data on clinical symptoms, TCM syndromes, prognosis, and multi-omics profiles, construct a spatiotemporal dynamic network for disease-syndrome evolution of acute ischemic stroke (AIS) in the acute and recovery phases, evaluate the efficacy and safety of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS, and provide evidence for precise syndrome differentiation and individualized therapy.Secondary Objective:To investigate the optimal time window and key intervention targets of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS.",[86,87,29],"Ischemic Strokes","Traditional Chinese Medicine (TCM)",[89,87,90,91],"Ischemic Stroke","Dianzhizhengmai Capsules","Dengzhanxixin Injection","2026-05-11",{"date":94,"type":35},"2026-05-18",{"date":37,"type":21},{"date":97,"type":21},"2029-07-31",{"name":99,"class":42},"Guangdong Provincial Hospital of Traditional Chinese Medicine",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":18,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100475779","personalized-first-line-chemotherapy-choice-in-advanced-pancreatic-adenocarcinoma-using-transcriptomic-signatures-100475779","NCT05475366","Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures","Pilot Study of Personalized First-line Chemotherapy Choice for Patients With Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures (PACsign)","PACsign","Inclusion Criteria:\n\n1. Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.\n2. Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n3. Histologically or cytologically proven Pancreatic Ductal Adenocarcinoma (PDAC).\n4. Metastatic disease.\n5. Measurable or evaluable lesions according to RECIST v1.1 criteria.\n6. First-line therapy (previous neoadjuvant\u002Fadjuvant chemotherapy not allowed).\n7. Age ≥ 18 years (no upper limit, patients ≥ 75 years old must have a G8 score ≥ 14).\n8. 3\\. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.\n9. Availability of tumor tissue sample from the primary pancreatic tumor or liver metastasis (chemo-naïve) before inclusion in step 1.\n10. Adequate organ function, as defined by the following (blood test ≤ 7 days prior to inclusion):\n\n    1. Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN) (≤ 5 ULN in case of liver metastases)\n    2. Total serum bilirubin ≤ 1.5 ULN\n    3. Serum albumin ≥ 28 g\u002FL\n    4. Hemoglobin ≥ 9.0 g\u002Fdl\n    5. Absolute neutrophil count (ANC) ≥ 1,500\u002FμL\n    6. Platelets ≥ 100,000\u002FμL\n    7. Creatinine clearance ≥ 50 mL\u002Fmin (MDRD).\n11. No Dihydropyrimidine dehydrogenase (DPD) deficiency (normal uracil level).\n12. Life expectancy ≥ 3 months.\n13. a. Evidence of post-menopausal status b. (or) negative urinary or serum pregnancy test for female pre-menopausal patients.\n14. Registration in a National Health Care System.\n\nExclusion Criteria:\n\n1. Concurrent enrolment in another interventional clinical study.\n2. Previous treatment with chemotherapy for pancreatic cancer.\n3. Uncontrolled massive pleural effusion or massive ascites.\n4. Known deficiency in UGT1A1 (homozygous UGT1A1\\*28 allele).\n5. Active bacterial, viral, or fungal infection requiring systemic therapy, including tuberculosis, hepatitis B (known positive Hepatitis B Virus surface antigen (HBsAg) result), hepatitis C (with positive RNA), Sars-Cov-2 or human immunodeficiency virus (positive HIV 1\u002F2 antibodies).\n6. Diagnosis of any second malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri.\n7. Known active central nervous system metastases and\u002For carcinomatous meningitis; patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline).\n8. Uncontrolled intercurrent illness, including but not limited to, symptomatic congestive heart failure or coronary disease, peripheral artery disease, severe chronic obstructive pulmonary disease, decompensated cirrhosis, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.\n9. Live vaccine administration within 30 days prior to the first dose of study treatment.\n10. Known or suspected allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n11. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the participant, in the opinion of the treating investigator.\n12. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.\n13. Major surgical procedure (as defined by the Investigator) within 4 weeks prior to the first dose of trial treatment.\n14. Pregnancy\u002Flactation.\n15. Person under legal protection or tutelage or guardianship.",{"count":109,"type":21},85,[24],"The aim of this study is to assess the clinical value of 5 transcriptomic signatures prognostic of chemotherapeutic sensitivity to improve the Objective Response Rate (ORR) of first-line (L1). Chemotherapy regimen (FOLFIRINOX vs Gem-nabP) will be selected based on transcriptomic signatures applied to the pre-therapeutic liver biopsy of newly diagnosed PDAC patients.",[113,29],"Carcinoma, Pancreatic Ductal",[115,116,117],"Transcriptomic signatures","Personalized first-line chemotherapy","Metastatic PDAC","RECRUITING","2026-04-30",{"date":121,"type":35},"2026-05-01",{"date":123,"type":35},"2022-12-12",{"date":125,"type":21},"2028-12-11",{"name":127,"class":42},"Institut Curie",7,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100572861","antimicrobial-therapy-for-difficult-to-treat-pseudomonas-aeruginosa-100572861","NCT06738771","Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa","Antimicrobial Therapy for Infections Due to Pseudomonas Aeruginosa With Difficult-to-treat Resistance: a Real-world, Prospective, Multicenter Cohort Study","ADDICT","Inclusion Criteria:\n\n* All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection\n\nExclusion Criteria:\n\n* Cystic fibrosis\n* P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic therapy\n* Protected person (under guardianship or curatorship)\n* Persons under court protection\n* Persons deprived of liberty\n* Opposition expressed for participation in the study",{"count":138,"type":21},600,"The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam\u002Fbeta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.",[141,142,29,143,144,145],"Pseudomonas Infections","Pseudomonas Aeruginosa","Drug Resistance, Multiple, Bacterial","Antibacterial Agents","Beta-lactam Antibiotics","2026-04-29",{"date":119,"type":35},{"date":149,"type":35},"2025-03-11",{"date":151,"type":21},"2027-01",{"name":153,"class":42},"Centre Hospitalier Régional d'Orléans",48,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100633463","phase-3-stratified-blood-pressure-management-after-endovascular-treatment-for-acute-ischemic-stroke-100633463","NCT07527013","Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke","Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke (RESCUE-BP)","RESCUE-BP","Inclusion Criteria:\n\n* Age ≥ 18 years；\n* Clinical diagnosis of acute ischemic stroke caused by anterior circulation large vessel occlusion (internal carotid artery or M1\u002FM2 segment of the middle cerebral artery)；\n* Received EVT (including direct EVT and bridging therapy) within 24 hours of symptom onset；\n* Baseline ASPECTS score ≥ 3；\n* Baseline NIHSS score ≥ 6；\n* Successful recanalization achieved post-procedure (defined as expanded Thrombolysis in Cerebral Infarction \\[eTICI\\] grade ≥ 2b50);\n* Two consecutive systolic blood pressure (SBP) measurements ≥ 150 mmHg within 3 hours post-recanalization (with a measurement interval of no less than 5 minutes)；\n* Able to complete randomization within 3 hours post-recanalization；\n* Informed consent signed by the patient or their legal representative.\n\nExclusion Criteria:\n\n* Pre-stroke mRS score \\> 1；\n* Comatose state (Glasgow Coma Scale \\[GCS\\] score \\\u003C 8);\n* Symptomatic intracerebral hemorrhage occurred before randomization;\n* Within the past 3 months, occurrence of acute ST-segment elevation myocardial infarction (MI), acute decompensated heart failure, QTc \\> 500 ms, hospitalization or involuntary coronary intervention due to acute coronary syndrome, MI, or cardiac arrest; or heart failure (New York Heart Association \\[NYHA\\] class III\u002FIV or left ventricular ejection fraction \\\u003C 35%); or known history of ventricular tachycardia;\n* History of severe renal insufficiency, acute renal failure, dialysis, or estimated glomerular filtration rate (eGFR) \\\u003C 20 ml\u002Fmin\u002F1.72m²;\n* History of severe hepatic disease, or Aspartate Aminotransferase (AST) and\u002For Alanine Aminotransferase (ALT) and\u002For Gamma-Glutamyl Transferase (GGT) ≥ 3×ULN and\u002For Total Bilirubin (TBIL) ≥ 2×ULN;\n* Aortic dissection, cervical artery dissection, or cerebral artery dissection; unruptured aortic aneurysm or cerebral aneurysm; or known arteriovenous malformation;\n* Comorbidities with a life expectancy \\\u003C 6 months (e.g., malignant tumors);\n* Pregnant or lactating women;\n* Participation in another clinical trial within the past 30 days;\n* Any clinical condition judged by the research team that might limit compliance with study procedures.",{"count":164,"type":21},544,[83],"The RESCUE-BP is a multi-centered, prospective, randomized, open label, blinded endpoint (PROBE) phase III trial. In patients with acute ischemic stroke who have undergone endovascular treatment and achieved successful recanalization, the evaluation will compare a stratified blood pressure management strategy based on the collateral circulation status with the guideline-recommended conventional blood pressure management strategy. Within each stratum, participants will be randomized in a 1:1 ratio to either the stratified blood pressure management strategy group or the guideline-recommended conventional blood pressure management group. The goal is to determine whether this can improve good functional outcomes at 90 days (90-day Modified Rankin Scale \\[mRS\\] score 0-2).\n\nThe study consists of four visits including the day of randomization, 24±4 hours after randomization, 7±1 days after randomization and 90±7 days after randomization. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment, neurological function rating scale will be recorded during the program.\n\nThe primary outcome is the modified Rankin Scale (mRS) score of 0 to 2 at 90±7 days after randomization. The primary safety outcome is the incidence of sICH within 24±4 hours after randomization.",[168,169,170,171,29],"Endovascular Therapy","Acute Ischaemic Stroke","Collateral Circulation","Blood Pressure Management","2026-04-17",{"date":174,"type":35},"2026-04-22",{"date":37,"type":21},{"date":177,"type":21},"2028-02-29",{"name":179,"class":42},"Beijing Tiantan Hospital",1,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":189,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":190,"targetDuration":192,"studyType":54,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":180},"100633517","cardiac-magnetic-resonance-clinical-prediction-model-dilated-cardiomyopathy-100633517","NCT07527715","Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy","Study on Risk Early Warning of Clinical Prediction Model Based on Multi-Parameter Stress Perfusion Cardiac Magnetic Resonance in Adverse Prognosis of Dilated Cardiomyopathy","MPS-CMR-DCM","Inclusion Criteria\n\n1.An elevated left ventricular end-diastolic volume indexed to body surface area and reduced LVEF, compared with published age- and gender-specific reference values Exclusion Criteria\n\n1. significant coronary artery disease (CAD), defined as a stenosis of ˃50% in a major coronary artery\n2. infiltrative disease\n3. valvular cardiomyopathy\n4. arrhythmogenic cardiomyopathy\n5. congenital heart disease",true,{"count":191,"type":21},2000,"6 Months","Dilated cardiomyopathy (DCM) is a common and serious heart disease characterized by left ventricular enlargement and impaired pumping function, with adverse prognosis (including heart failure, arrhythmia, heart-related hospitalization, and death) being a major concern for patients. Currently, a critical gap exists in accurately predicting which DCM patients are at high risk of these severe outcomes, limiting targeted clinical care.\n\nThis observational, non-invasive study aims to develop and validate a clinical prediction model for early risk warning of adverse prognosis in DCM patients. The model integrates multi-parameter stress perfusion cardiac magnetic resonance (MP stress perfusion CMR)-a safe, high-resolution imaging technique that assesses cardiac structure, function, blood perfusion, and tissue damage under mild stress-and standard clinical data (e.g., age, gender, blood pressure, and routine heart test results).\n\nThe model will be trained and tested using follow-up data from hundreds of DCM patients, with the analysis identifying patterns in CMR and clinical data associated with adverse outcomes. Once validated for accuracy, the model will provide doctors with personalized risk scores to prioritize care for high-risk patients (e.g., early intervention, close monitoring) and avoid over-treatment for lower-risk individuals.\n\nBeyond clinical application, the study will enhance understanding of DCM progression, laying the groundwork for improved diagnostic tools, more effective treatments, and better strategies to prevent DCM-related complications, ultimately improving patient quality of life and reducing mortality.",[195,29,196,197,198,199,200],"Cardiomyopathy, Dilated","Magnetic Resonance Imaging, Cardiac","Death, Sudden, Cardiac","Heart Failure","Risk Assessment","Stress Perfusion","2026-04-09",{"date":203,"type":35},"2026-04-14",{"date":205,"type":35},"2021-12-01",{"date":207,"type":21},"2038-12-01",{"name":209,"class":210},"Shandong Provincial Hospital","OTHER_GOV",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":219,"enrollmentInfo":220,"targetDuration":222,"studyType":54,"phases":4,"briefSummary":223,"conditions":224,"keywords":231,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":180},"100601955","validation-of-rcc-predicting-model-with-emulated-target-trial-100601955","NCT07117227","Validation of RCC Predicting Model With Emulated-target Trial","Emulated-target Trial for Guiding Stratified Treatment for Renal Cell Carcinoma With Venous Tumor Thrombus","RCCETT","Inclusion Criteria:\n\n* Adults ≥18 years of age;\n* Diagnosis of primary renal cell carcinoma before and during the surgery;\n* Received radical nephrectomy\u002Fnephron-sparing surgery.\n\nExclusion Criteria:\n\n* Subjects with severely missing clinical information;\n* History of other malignant tumors.\n* Recurrence observed before first postoperative follow-up.\n* Discontinue the adjuvant treatment within in the first two course because of severe adverse react.","80 Years",{"count":221,"type":21},4700,"2 Years","This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high\u002Fmedium\u002Flow risk) improves survival outcomes .",[225,226,227,29,228,229,230],"Renal Cell Carcinoma (Kidney Cancer)","Renal Cell Carcinoma (RCC)","Tumor Thrombus","Prognostic Cancer Model","Real World Study","Observational Study",[232,233,234,235],"renal cell carcinoma","tumor thrombus","prognostic model","emulated-target trial","2026-04-08",{"date":203,"type":35},{"date":239,"type":35},"2025-09-01",{"date":241,"type":21},"2027-08-01",{"name":243,"class":42},"Peking University Third Hospital",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":258,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":180},"100631918","neuro---prognostication-using-late-somatosensory-evoked---potentials-100631918","NCT07506928","NEURO - Prognostication Using Late Somatosensory Evoked - Potentials","NEURO-PULSE","Inclusion Criteria:\n\n* Patients must be aged 18 years or over;\n* Patients must be admitted to the intensive care unit with a cerebrovascular pathology;\n* Patients must be in a comatose state with a Glasgow score strictly less than 8, 24 hours after stopping sedation.\n* Representative of the patient informed of the research and not objecting to it, information and collection of the participant's non-objection if recovery of the ability to understand the content of the information note,\n* The patient is a recipient of or affiliated with a social security scheme.\n\nExclusion Criteria:\n\n* Bilateral lesions of the motor cortex or cortico-spinal fasciculus,\n* Cutaneous infection of the scalp or any other lesion making surface electroencephalography impossible,\n* Patient whose short-term survival (48 - 72 hours) seems compromised,\n* Severe peripheral neuromyopathy,\n* Severe Acute Respiratory Distress Syndrome at the time of screening,\n* Hearing-impaired patients with hearing aids,\n* Pregnant or breastfeeding woman,\n* Patient under legal protection (persons deprived of their liberty or under guardianship).",{"count":252,"type":21},50,[24],"The main aim of this study is to develop a new technique for the passive diagnosis of cognitive-motor dissociation, with the detection of motor intention in a comatose patient by analysing the EEG signal and in particular the ERD\u002FERS amplitudes in the motor cortex after stimulation of the median nerve.",[256,29,257],"Comatose","Critical Care",[259,260,261,262,263],"Prognostication","Somatosensory evoked - potentials","Neurocritical care","Machine learning","Continuous EEG","2026-03-26",{"date":266,"type":35},"2026-04-02",{"date":268,"type":21},"2026-06-30",{"date":270,"type":21},"2028-06-30",{"name":272,"class":42},"University Hospital, Bordeaux",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":180},"100504438","preoperative-serum-fgf19-in-the-prognosis-of-biliary-atresia-100504438","NCT05848310","Preoperative Serum FGF19 in the Prognosis of Biliary Atresia","Inclusion Criteria:\n\n* Samples diagnosed as biliary atresia in Children's Hospital of Fudan University\n* Samples with one-year follow-up records after surgery\n* Samples with a record of serum total bilirubin levels three months after surgery\n* Samples with preoperative serum left（volume \\> 500ul)\n\nExclusion Criteria:\n\n* None",{"count":280,"type":21},200,"To investigate the role of preoperative serum FGF19 level in the prognosis of biliary atresia.",[283,29],"Biliary Atresia",[283,285],"FGF19","2026-03-24",{"date":288,"type":35},"2026-03-27",{"date":290,"type":35},"2023-10-15",{"date":292,"type":21},"2027-08",{"name":294,"class":42},"Children's Hospital of Fudan University",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":320},"100306395","thrombus-composition-in-ischemic-stroke-analysis-of-the-correlation-with-plasma-biomarkers-efficacy-of-treatment-etiology-and-prognosis-100306395","NCT03268668","Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis","COMPO-CLOT","Inclusion Criteria:\n\n* Patients aged 18 years and older\n* Presenting with cerebral infarction following arterial occlusion\n* Treated for mechanical thrombectomy (whether performed or not)\n* Free, informed, and express consent of the patient or their relatives (emergency inclusion procedure)\n* For retrospective patients: thrombus already collected (according to the center's usual practice or for another research project).\n\nExclusion Criteria:\n\n* Patient benefiting from a legal protection measure\n* Pregnant or breastfeeding woman",{"count":303,"type":21},1200,"The recent validation of thrombectomy in addition to thrombolysis with intravenous administration of alteplase suggests a major revolution in the management of acute strokes. This treatment option also opens up a new field of research, making possible the analysis of the clot responsible for intracranial occlusion. Indeed, in about 30% of the cases, the thrombectomy procedure makes it possible to retrieve either partially or completely the clot. Previous studies have analyzed the correlation between the composition of the thrombus and the etiology of stroke. Their discordant results do not yet make it possible to distinguish a particular profile of thrombus according to etiology. Other studies have shown a correlation between the proportion of red blood cells in a thrombus and the likelihood that it is visible in MRI or cerebral scanning. More recently, one study has demonstrated a correlation between the presence of lymphocytes in the thrombus and an atheromatous etiology.\n\nThe main limitations of these studies are the small number of patients included, the high variability of conservation protocols and the absence of plasma data, which does not allow for research on the correlation between clot composition and plasma biomarkers.",[306,307,308,309,29],"Stroke, Acute","Biological Specimen Banks","Biomarkers","Etiology","2026-01-16",{"date":312,"type":35},"2026-01-20",{"date":314,"type":35},"2017-07-13",{"date":316,"type":21},"2028-01-01",{"name":318,"class":319},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",12,{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":339,"locationsCount":4},"100613693","application-of-multimodal-mri-in-histological-grading-and-prognostic-assessment-of-rectal-cancer-100613693","NCT07269912","Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer","Sub-region Analysis Based on Intravoxel Incoherent Motion MRI for Preoperative Prediction of Lymphovascular Invasion and Prognosis in Rectal Cancer","Inclusion Criteria:\n\n* (1) patients underwent preoperative abdominal pelvic IVIM-MRI examination; (2) patients underwent surgical resection within 2 weeks after IVIM-MRI examination; (3) complete postoperative pathological data, including LVI status.\n\nExclusion Criteria:\n\n* (1) radiotherapy or chemotherapy before surgery; (2) preoperative metastatic disease; (3) poor image quality; (4) incomplete clinical data.",{"count":329,"type":21},400,"Rectal cancer (RC) is among the most prevalent gastrointestinal cancers \\[1\\], characterized by significant tumor heterogeneity \\[2\\]. Neoadjuvant chemoradiotherapy followed by total mesorectal excision is a standard treatment for locally advanced rectal cancer \\[3\\]. Although the locoregional recurrence rate has decreased due to this treatment, distant metachronous metastases still occur in over 20-30% of cases \\[4,5\\]. The varying biological characteristics of rectal cancer may result in different treatment responses and prognoses \\[6\\]. Patients who are diagnosed with the same tumor-node-metastasis (TNM) stage of RC frequently exhibit vastly different clinical outcomes, despite receiving the same therapeutic interventions \\[7\\]. While the TNM staging system remains the predominantly used framework for directing treatment choices and forecasting prognosis, it is crucial to take into account additional pathological elements, such as tumor budding, lymphovascular invasion (LVI), perineural invasion, and extramural venous invasion \\[8-10\\]. A recent investigation has highlighted that LVI, rather than the traditionally prioritized extent of tumor invasion, serves as a significant risk factor for metastasis in early-stage RC \\[11\\]. Patients exhibiting LVI+ demonstrate a considerably worse prognosis and overall survival when compared to those with LVI -. Identifying LVI before surgery is crucial for informing treatment strategies in RC \\[12\\]. LVI offers important information regarding the tumor's biological behavior and its likelihood of metastasizing, thus improving the precision of disease staging. This information enables clinicians to tailor treatment approaches, which helps prevent overtreatment in patients with LVI -. In cases where LVI is present, it may be essential to adopt more aggressive treatment methods, such as postoperative chemotherapy, radiotherapy, or more extensive surgical resections, to reduce the chances of recurrence and metastasis. In summary, LVI serves as a crucial prognostic factor, providing essential insights into the tumor's potential for metastasis and recurrence, which has significant clinical implications for predicting postoperative outcomes, including recurrence, metastasis, and disease-free survival. Therefore, a preoperative non-invasive assessment of LVI, particularly in patients with LVI +, may be instrumental in guiding clinical practice.\n\nConventional magnetic resonance imaging (MRI) is particularly effective in observing large blood vessels and has moderate sensitivity and high specificity to distinguish LVI \\[13\\]. However, it can noninvasively and accurately assess extramural vascular invasion with a diameter greater than 3 mm. In contrast, it is challenging to evaluate vascular invasion with a diameter less than 3 mm, as well as intramural vascular and lymphatic infiltration, due to the limitations in resolution \\[14,15\\]. In addition, pathological biopsy is the gold standard for preoperative diagnosis. However, this invasive approach may not reflect the LVI status of the entire tumor due to possible sample errors \\[16\\]. Therefore, effectively assessing LVI in RC via preoperative imaging remains a significant challenge.\n\nIntravoxel incoherent motion (IVIM) is a functional imaging method that can display the diffuse movement of water molecules and blood flow, microcirculation perfusion, thereby improving the diagnostic accuracy of RC \\[17,18\\]. The IVIM model has the potential to identify perfusion effects using multiple b-value samples and biexponential curve fit analysis \\[19\\], which can lead to three parameters, namely the true diffusion coefficient (D), the pseudo-diffusion coefficient (D\\*), and the perfusion fraction (f). Li et al \\[20\\]. discovered that the D value obtained from IVIM of LVI+ patients was significantly higher than that of LVI- patients with RC, but only 42 patients were included in this study, making it more difficult to accurately assess the feasibility of IVIM. In another study, Kan et al \\[21\\]. revealed that the D value was helpful to assess the prognostic factor related to RC, while the AUC of the D value for evaluating LVI was only 0.646. Currently, studies utilizing conventional IVIM quantitative parameters have demonstrated a relatively low diagnostic efficiency in detecting LVI, with AUC values ranging from 0.629 to 0.646 \\[22,23\\].\n\nTumor heterogeneity has emerged as a significant biomarker for tumor staging and prognosis \\[24\\]. Sub-region analysis, an innovative imaging post-processing technique, has demonstrated its potential in exploring intratumor heterogeneity in recent years. Prior research has underscored the importance of sub-region analysis derived from either single-modality or multiparametric MRI in the investigation of intratumor heterogeneity in RC \\[25-27\\]. However, to our knowledge, the application of sub-region analysis based on IVIM-MRI to evaluate LVI status and prognosis in patients with RC has not been reported. Thus, this study aimed to assess the fe",[332,29],"Rectal Neoplasms","2025-11-26",{"date":335,"type":35},"2025-12-08",{"date":337,"type":21},"2027-11-01",{"date":337,"type":21},{"name":340,"class":42},"Sichuan Cancer Hospital and Research Institute",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":348,"targetDuration":350,"studyType":54,"phases":4,"briefSummary":351,"conditions":352,"keywords":356,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":180},"100604450","pbc-long-term-outcomes-study-100604450","NCT07149675","PBC Long-term Outcomes Study","A Multi-center Prospective-retrospective Study of the Clinical Characteristics, Biochemical Response, and Long-term Outcomes in Patients With Primary Biliary Cholangitis","Inclusion Criteria:\n\n* Diagnosis consistent with PBC.\n* Willingness to participate, with informed consent obtained from the patient or legal representative (if the patient is deceased or cognitively impaired), and ability to adhere to follow-up.\n\nExclusion Criteria:\n\n* Co-existing chronic hepatitis B or C, drug-induced liver injury, autoimmune hepatitis, primary sclerosing cholangitis, or hereditary\u002Fmetabolic liver diseases.\n* Co-existingMalignancy or severe cardiac, pulmonary, renal, cerebral, or hematologic disorders expected to substantially shorten life expectancy.\n* Incomplete baseline medical records or laboratory data.",{"count":349,"type":21},4000,"3 Years","Primary biliary cholangitis (PBC) is an autoimmune liver disease predominantly affecting middle-aged women. While historically it was deemed rare, advancements in specific auto-antibody tests have led to increased recognition of PBC. The long-term survival of PBC patients in China is not yet fully understood. Several studies have investigated the prognosis of PBC in China. While these studies provide valuable insights into the disease characteristics and prognostic factors of PBC in China, they are all single-center studies with limitations. They lack consideration of the impact of symptoms, varying disease stages, and second-line treatments on prognosis. Therefore, there is a pressing need for multicenter and large-scale studies to further elucidate the characteristics and long-term survival of PBC patients in China.\n\nBiochemical response to ursodeoxycholic acid (UDCA) is an independent factor associated with long-term survival. Unfortunately, approximately 30-40% of PBC patients demonstrate insufficient biochemical response to UDCA. In our cohort, we reported a higher nonresponse rate, with about 44% according to the Paris I criteria. These patients remain at risk for disease progression to advanced stages and may benefit from additional second-line drug therapies. With significant advancements in the development of new drugs for PBC, a comprehensive understanding of patients with suboptimal responses to UDCA-including long-term prognosis, the distribution of different disease stages, and the prevalence of pruritus-will provide a basis for individualized treatment strategies.\n\nAdditionally, fatigue and pruritus are prevalent symptoms for PBC patients and fluctuates independently of disease activity or stage, which significantly diminishing health-related quality of life. However, the incidence and impact of fatigue and pruritus on long-term outcomes for PBC patients in China need further clarification.\n\nTherefore, we would like to conduct this multicenter study to estimate the prevalence of PBC in China and to evaluate the symptomatic burden, treatment, and long-term outcomes among PBC patients in China.",[353,354,29,355],"Primary Biliary Cholangitis (PBC)","Long-term Outcomes","Multicenter Prospective Study",[357,358,359,360,361],"Primary biliary cholangitis","long-term outcomes","prognosis","multicenter","Symptoms","2025-08-24",{"date":364,"type":35},"2025-09-02",{"date":366,"type":35},"2025-05-18",{"date":368,"type":21},"2029-12-31",{"name":370,"class":42},"Beijing Friendship Hospital",{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":382,"conditions":383,"keywords":390,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":399,"completionDateStruct":401,"leadSponsor":403,"locationsCount":405},"100477248","impact-of-erector-spinae-plane-block-on-chronic-postsurgical-pain-in-breast-cancer-patients-100477248","NCT05494502","Impact of Erector Spinae Plane Block on Chronic Postsurgical Pain in Breast Cancer Patients","Impact of Erector Spinae Plane Block With Adjuvant Dexmedetomidine on Chronic Postsurgical Pain in Breast Cancer Patients: a Two-center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age of 18 years or over, but less than 85 years;\n2. Scheduled to undergo mastectomy for primary unilateral breast cancer.\n\nExclusion Criteria:\n\n1. Previous breast cancer surgery with an incision of \\>2 cm;\n2. Chronic opioid dependence or long-term intake of analgesic medicines (\\>3 months);\n3. Any contraindication to erector spinae plane block, including intrathoracic infection, infection at the puncture site, cancer invasion of the puncture site, severe spinal deformity, history of spinal surgery, and severe coagulopathy;\n4. Inability to communicate in the preoperative period because of profound dementia, deafness, language barriers, or end-stage disease;\n5. History of malignant tumor in other organs, or a current combination of malignant tumor of other organs;\n6. History of coronary heart disease (diagnosed coronary stenosis, previous myocardial infarction, previous percutaneous coronary intervention or coronary artery bypass grafting); preoperative hepatic or renal impairment (alanine transaminase and\u002For aspartate transaminase ≥2 times of upper limit of normal, or serum creatinine\\>133 µmol\u002FL); history of peptic ulcer or hemorrhage; ASA classification IV or above;\n7. Allergy to ropivacaine.","85 Years",{"count":380,"type":21},1206,[24],"Chronic postsurgical pain (CPSP) has an incidence of 46% in patients after breast cancer surgery, which seriously affects patients' physiological and psychological function, as well as quality of life. Acute pain is an independent risk factor for persistent pain after surgery. Erector spinae plane block (ESPB) provided excellent perioperative analgesia in patients undergoing breast surgery. Dexmedetomidine as an adjuvant of local anesthetics prolongs the duration of peripheral nerve block and decreases the requirements of postoperative analgesia. The investigators hypothesize that, for breast cancer patients undergoing mastectomy, ESPB (with a combination of 0.5% ropivacaine 35 ml and dexmedetomidine 1 microgram\u002Fkg) can reduce the occurrence of CPSP. The purpose of this randomized controlled trial is to investigate the impact of ESPB with adjuvant dexmedetomidine on the incidence of CPSP in breast cancer patients after mastectomy. We will also observe the impact of ESPB on long-term survival in these patients.",[384,385,386,387,388,389,29],"Breast Neoplasms","Mastectomy","Nerve Block","Dexmedetomidine","Pain, Postoperative","Chronic Pain",[391,385,392,387,393,394,395],"Breast cancer","Erector spinae plane block","Postoperative pain","Chronic postsurgical pain","Long-term prognosis","2025-07-29",{"date":398,"type":35},"2025-07-31",{"date":400,"type":35},"2023-05-23",{"date":402,"type":21},"2027-07",{"name":404,"class":42},"Peking University First Hospital",2,{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":180},"100598281","prognostic-value-of-isolated-and-combined-score-aspects-in-acute-ischemic-stroke-100598281","NCT07069452","Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke","TARGET-ASPECT (Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke)","Inclusion Criteria :\n\n* Patients aged 18 years or older\n* Confirmed acute ischemic stroke on imaging\n* Treated with both thrombolysis and thrombectomy\n* Clinical follow-up data available at 90 days (mRS score)\n\nExclusion Criteria :\n\n* Primary hemorrhagic stroke\n* Early death or loss to follow-up without evaluation\n* Poor-quality imaging that cannot be analyzed",{"count":414,"type":21},152,"This study, called TARGET-ASPECT, looks at patients who had a type of stroke called acute ischemic stroke and were treated with clot-busting medicine and a procedure to remove the clot. Even with these treatments, about half of patients don't fully recover. The study aims to see if certain brain imaging scores, especially when combined, can better predict how well patients will recover 90 days after their stroke and if their blood vessels reopen successfully. The study will include 152 patients and last about 9 months. The goal is to find easy and reliable tools that doctors can use to make better treatment decisions.",[417,418,419,420,29,421,422],"Stroke, Ischemic","Thrombectomy","Thrombolytic Therapy","Brain Ischemia","Magnetic Resonance Imaging","Outcome Assessment (Health Care)","2025-07-15",{"date":425,"type":35},"2025-07-16",{"date":427,"type":35},"2025-04-15",{"date":429,"type":21},"2026-01-15",{"name":431,"class":42},"Centre Hospitalier de Gonesse",{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":22,"phases":441,"briefSummary":442,"conditions":443,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":454},"100599007","effect-of-bone-augmentation-simultaneous-to-implant-removal-on-the-prognosis-of-reimplantation-at-the-same-site-100599007","NCT07078890","Effect of Bone Augmentation Simultaneous to Implant Removal on the Prognosis of Reimplantation at the Same Site","Inclusion Criteria:\n\n* 1\\. Age greater than 18 years 2. Implant failure requiring removal 3. Plan to reimplant in the same site 4. Periodontal health, or stabilized periodontitis after treatment\n\nExclusion Criteria:\n\n* 1\\. Uncontrolled metabolic diseases 2. Taking medications that have an effect on bone metabolism 3. The implant has detached at the time of consultation 4. Do not consent to reimplant in the same site 5. Unwillingness to participate in the follow-up of this study 6. Other conditions that do not qualify for implant therapy","90 Years",{"count":440,"type":21},40,[24],"The aim of this study was to investigate the effect of bone augmentation simultaneous to implant removal on the prognosis of reimplantation at the same sites, providing recommendations for management strategies after failed implant removal.",[444,445,29],"Implant Failure","Bone Augmentation","2025-07-13",{"date":448,"type":35},"2025-07-22",{"date":450,"type":35},"2025-03-12",{"date":292,"type":21},{"name":453,"class":42},"The Dental Hospital of Zhejiang University School of Medicine",3,{"id":456,"slug":457,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":219,"enrollmentInfo":463,"targetDuration":465,"studyType":54,"phases":4,"briefSummary":466,"conditions":467,"keywords":474,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":180},"100598543","using-cardiac-mri-to-predict-outcomes-in-patients-with-stemi-100598543","NCT07072858","Using Cardiac MRI to Predict Outcomes in Patients With STEMI","Prognostic Value of Cardiac Magnetic Resonance Parameters in Patients With ST-Segment Elevation Myocardial Infarction","CMR-RISK-STEMI","Inclusion Criteria:\n\n* Age between 18 and 80 years\n\nDiagnosed with ST-segment elevation myocardial infarction (STEMI), defined as chest pain with ST-segment elevation on ECG and elevated cardiac troponin levels\n\nUnderwent primary percutaneous coronary intervention (PCI)\n\nAble to undergo cardiac magnetic resonance (CMR) imaging within 7 days post-PCI\n\nProvided written informed consent\n\nExclusion Criteria:\n\n* Contraindications to CMR (e.g., severe claustrophobia, implanted cardiac defibrillators or non-compatible pacemakers)\n\nHistory of revascularization therapy (PCI or CABG) within the previous 6 months\n\nSevere valvular heart disease or known cardiomyopathy\n\nPresence of bundle branch block or fascicular block that interferes with image interpretation\n\nKnown allergy to gadolinium-based contrast agents (for those undergoing contrast-enhanced sequences)\n\nEstimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73m² (if contrast use is anticipated)\n\nPregnant or breastfeeding women",{"count":464,"type":21},1000,"5 Years","This prospective, multicenter observational study aims to evaluate the prognostic value of a comprehensive set of cardiac magnetic resonance (CMR) imaging parameters in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The study integrates advanced artificial intelligence (AI) techniques to extract and analyze high-dimensional imaging features from multiple CMR sequences-including cine, strain mapping, and functional sequences-going beyond traditional measures such as infarct size or microvascular obstruction.\n\nThe primary objective is to identify novel prognostic markers from routinely acquired CMR images that reflect myocardial structure, function, and mechanical deformation (strain), and to assess their association with long-term clinical outcomes. In addition to standard parameters, the study includes a detailed evaluation of left and right ventricular systolic and diastolic volumes, ejection fractions, and biventricular strain components (including longitudinal, circumferential, and radial strain), as well as left and right atrial volumes, emptying fractions, and reservoir\u002Fconduit\u002Fbooster strain indices.\n\nApproximately 1000 STEMI patients will undergo CMR scanning within one week after PCI. The imaging data will be subjected to AI-based feature extraction and dimensionality reduction algorithms to uncover latent patterns associated with adverse outcomes. Patients will be followed for up to three years for the occurrence of major adverse cardiovascular events (MACE), including cardiovascular death, recurrent myocardial infarction, and heart failure hospitalization.\n\nThe central hypothesis is that comprehensive CMR functional and strain-derived parameters, when analyzed using AI-driven models, offer independent and incremental prognostic value beyond conventional clinical risk factors. This study seeks to establish a data-driven, multimodal imaging framework for personalized risk stratification in STEMI patients, potentially enabling more precise post-infarction management strategies.\n\nNo investigational treatment is involved. All imaging and clinical data are collected as part of routine care and analyzed retrospectively for outcome prediction.",[468,469,470,471,472,29,473],"Myocardial Infarction (MI)","ST Segment Elevation Myocardial Infarction (STEMI)","Magnetic Resonance Imaging (MRI)","Heart Ventricles","Artificial Intelligence (AI)","Ventricular Dysfunction",[475,476,477,478,479,480,481],"ST Segment Elevation Myocardial Infarction","Cardiac Magnetic Resonance Imaging","Cardiac Strain Imaging","Machine Learning","Image Analysis","Survival Analysis","Multimodal Imaging","2025-07-09",{"date":484,"type":35},"2025-07-18",{"date":486,"type":35},"2014-01-01",{"date":488,"type":21},"2025-12-30",{"name":490,"class":42},"Chinese PLA General Hospital",{"id":492,"slug":493,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":498,"targetDuration":499,"studyType":54,"phases":4,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":180},"100552036","predicting-ventilator-associated-lower-respiratory-tract-infection-outcomes-using-sequenced-based-early-microbiological-response-100552036","NCT06467864","Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response","Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response: A Multi-center Prospective Study","Inclusion Criteria:\n\n* Aged 18 years and above.\n* Previously relied on mechanical ventilation (endotracheal intubation or tracheotomy) for breathing assistance, and the duration of mechanical ventilation was more than 48h.\n* Lower respiratory tract infection based on at least two of the followings: abnormal temperature (body temperature greater than 38.5°C or less than 36.5°C), leucocyte count abnormality (leucocyte count greater than 12\\*10\\^9\u002FL or less than 4\\*10\\^9\u002FL), and the presence of purulent tracheal secretions.\n\nExclusion Criteria:\n\n* Bronchoscopy and respiratory specimen collection were not performed at screening (Day 1) and after 3 days of treatment (Day 4).\n* Refusal of patients or families to participate in the study\n* After initial screening, bronchoscopy was performed to obtain BALF for bacterial culture. The results of the culture showed no evidence of infection by study-associated lower respiratory pathogens.\n\nNote: The evidence of infection was defined as a single positive bacterial culture (pathogen quantification ≥10\\^4 cfu\u002Fml or \"++\" and more) on Day1. And the study-associated causative pathogens are Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, and Staphylococcus aureus. Additionally, the included patient must have single infection with one of these pathogens.",{"count":280,"type":21},"28 Days","We are using a tool called QtNGS (quantitative targeted amplicon-based next-generation sequencing ) to measure the abundance of local pathogens in patients with ventilator-associated lower respiratory tract infections. We hypothesize that changes in pathogen abundance before and after treatment are related to patient outcomes. This study aims to evaluate the effectiveness of the tool by analyzing the changes in pathogen abundance and exploring the relationship between these changes and clinical outcomes.",[502,503,29],"Pneumonia, Ventilator-Associated","Respiratory Tract Infections","2025-05-22",{"date":506,"type":35},"2025-05-23",{"date":508,"type":35},"2024-04-01",{"date":510,"type":21},"2026-01-29",{"name":512,"class":42},"The First Affiliated Hospital with Nanjing Medical University",{"id":514,"slug":515,"hasResults":11,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":22,"phases":523,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":454},"100586158","effect-of-the-postoperative-trendelenburg-position-on-chronic-subdural-hematoma-recurrence-100586158","NCT06911736","Effect of the Postoperative Trendelenburg Position on Chronic Subdural Hematoma Recurrence","Effect of the Postoperative Trendelenburg Position on Chronic Subdural Hematoma Recurrence: a Clinical Trial","POTHeR","Inclusion Criteria:\n\n* The study included patients aged 18 years or older who required surgical management of symptomatic CSH confirmed by CT scan and whose informed consent was given by the patient or responsible family member to participate in the study\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Conditions in which the trendelenburg position might not be safe, such as intracranial hypertension without a drain to allow evacuation of the hematoma, cardiovascular instability (severe heart failure, unstable angina, cardiogenic pulmonary edema), acute respiratory distress syndrome without a secure airway, glaucoma, spinal cord trauma not stabilized with surgery, peripheral vascular disease,\n* History of ipsilateral chronic subdural hematoma drainage, intracranial hypotension syndrome, ventriculoperitoneal shunting\n* Simultaneous participation in any other clinical trial.",{"count":522,"type":21},254,[24],"Objective: Determine the effect of the postoperative trendelenburg position on the recurrence of chronic subdural hematoma (CSH) in patients undergoing surgery.\n\nMaterials and Methods: An open-label, randomized, controlled clinical trial was conducted in three hospitals in Medellín. Patients with CSH were enrolled and assigned to the trendelenburg position (30° leg elevation and 10° head tilt) or a flat bed for 24 hours postoperatively. CSH recurrence was measured at 3 months, along with functional outcome (modified Rankin scale), adverse events, and comfort (Likert scale).",[526,527,528,529,29,530],"Chronic Subdural Hematoma","Trendelenburg","Recurrence","Mortality","Clinical Trials","2025-04-16",{"date":533,"type":35},"2025-04-22",{"date":535,"type":35},"2024-06-01",{"date":537,"type":21},"2027-04-30",{"name":539,"class":42},"Universidad de Antioquia",{"id":541,"slug":542,"hasResults":11,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":219,"enrollmentInfo":546,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":547,"conditions":548,"keywords":553,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":180},"100566442","profiling-the-intratumoral-microbiome-of-pancreatic-ductal-adenocarcinoma-based-on-eus-fnb-tissue-samples-and-exploring-its-impact-on-tumor-diagnosis-and-prognosis-100566442","NCT06655233","Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis.","Inclusion Criteria:\n\n1. Males or females aged between 18 and 80 years.\n2. Patients with pancreatic lesions confirmed through imaging examinations (US, MRI, CT, or PET-CT) with a high suspicion of pancreatic ductal adenocarcinoma (PDAC) who require EUS-FNB for diagnostic assistance.\n3. Patients who have not received any chemotherapy, including neoadjuvant, postoperative adjuvant, or palliative chemotherapy.\n4. Patients who agree to participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Poor physical condition, including but not limited to hemoglobin ≤ 8.0 g\u002Fdl, severe cardiopulmonary insufficiency, etc.\n2. Coagulation disorders (platelet count \\\u003C 50 × 10\\^9\u002FL, international normalized ratio \\> 1.5).\n3. Failed anesthesia evaluation.\n4. Acute pancreatitis within the past 2 weeks.\n5. Pregnant or breastfeeding individuals.\n6. Mental illness, drug addiction, or other conditions that may affect follow-up.\n7. Patients who have received antibiotic treatment before the biopsy procedure or other conditions deemed unsuitable by the investigators.",{"count":252,"type":21},"The goal of this observational study is to use endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) to investigate the intratumoral microbiome profile in patients with pancreatic ductal adenocarcinoma (PDAC) and to evaluate its potential impact on tumor diagnosis and prognosis. PDAC is the most common and lethal type of pancreatic cancer, accounting for over 85% of all pancreatic cancer cases. Given that most patients are diagnosed at an advanced stage when surgery is no longer an option, EUS-FNB serves as a crucial and minimally invasive method for accessing and analyzing the microbiome within the tumor.\n\nThe main questions this study aims to answer are:\n\nCan EUS-FNB reliably and accurately detect the microbiome within PDAC tumors?\n\nResearchers will analyze tissue samples obtained through EUS-FNB to confirm its ability to accurately capture the diversity and composition of the tumor microbiome.\n\nAre there specific microbes or metabolites within the PDAC tumor microbiome that are linked to patient prognosis or response to chemotherapy?\n\nThe study will screen for and identify key microbial species or metabolites associated with treatment outcomes and patient survival in PDAC.\n\nTo ensure the reliability of the EUS-FNB results, researchers will systematically compare microbiome data obtained from EUS-FNB samples with those from surgical biopsies of pancreatic cancer tissue. This comparison will help validate the consistency and accuracy of the two methods in identifying the microbiome diversity and composition, confirming the clinical and research utility of EUS-FNB.\n\nParticipant Requirements:\n\nParticipants will be patients diagnosed with PDAC who require EUS-FNB as part of their clinical assessment and treatment pathway.\n\nDuring the EUS-FNB procedure, researchers will use the remaining tissue after rapid on-site evaluation (ROSE) to conduct microbiome sequencing, ensuring sample quality.\n\nAll participants will provide informed consent, allowing the use of leftover tissue for microbiome analysis, and their privacy will be strictly protected throughout the study.\n\nStudy Procedures:\n\nParticipants will undergo a standard EUS-FNB procedure as part of their routine clinical care, with no additional procedures required for the study.\n\nResearchers will compare the microbiome characteristics from EUS-FNB samples with those from surgical biopsy samples to verify consistency.\n\nThe study will utilize 2bRAD-M metagenomic sequencing technology, which is cost-effective and suitable for low-biomass, host-contaminated, and degraded microbiome samples. This method generates an accurate species-level taxonomic profile for analysis.\n\nBy identifying key microbial components or metabolites linked to patient prognosis or treatment response, this study aims to provide scientific evidence for early detection strategies and effective treatment plans for PDAC patients, potentially bringing significant clinical benefits.",[549,550,551,552,29],"Pancreatic Cancer","EUS-FNB","Intratumoral Microbiota","Diagnosis",[554,550,555,556,29],"pancreatic cancer","intratumoral microbiota","diagnosis","2024-10-22",{"date":559,"type":35},"2024-10-23",{"date":561,"type":35},"2024-10-01",{"date":563,"type":21},"2026-05-30",{"name":565,"class":42},"The Third Xiangya Hospital of Central South University",{"id":567,"slug":568,"hasResults":11,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":573,"targetDuration":575,"studyType":54,"phases":4,"briefSummary":576,"conditions":577,"keywords":579,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":180},"100555335","evaluation-of-the-levels-of-calcitonin-gene-related-peptide-and-substance-p-100555335","NCT06510751","Evaluation of the Levels of Calcitonin Gene-related Peptide and Substance P","Evaluation of the Levels of Calcitonin Gene-related Peptide and Substance P in Patients With Post-operative Meningitis","Inclusion Criteria:\n\n* Patients aged 18 years and over\n* Patients followed up in the intensive care unit with suspected meningitis\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Patients with suspected meningitis in the intensive care unit who have not undergone neurosurgical operation and do not have CSF drainage catheter",{"count":574,"type":21},51,"16 Months","In cases of meningitis caused by external ventricular catheters (EVDs), which are the most commonly placed intracranial catheters that can lead to central nervous system infection through contamination\u002Fcolonisation, the diagnosis may not be differentiated by either clinical signs and symptoms or conventional cerebrospinal fluid (CSF) tests. Therefore, due to the limitations in diagnosis and prognostic prediction of EVD-induced meningitis and the high mortality\u002Fmorbidity rates of the disease, markers with high sensitivity and specificity in post-operative meningitis are needed. Calcitonin gene-related peptide (CGRP), a neuropeptide, has been shown to increase when C or Aδ sensory fibres are damaged or in the presence of inflammation in tissues adjacent to the fibres. CGRP is localised in nociceptive nerve terminals together with another neuropeptide, substance P, which has similar biological effects. There are very few studies investigating how CGRP levels in CSF and serum change in bacterial meningitis. Although it is thought that nociception and neuroimmune interactions affect meningeal antibacterial host defence, that nociceptors signal via CGRP to meningeal immune cells during infection, and that this neuroimmune axis exacerbates bacterial meningitis by weakening host defence, it is not yet clear how CGRP and substance P levels affect disease prognosis. This study will evaluate the utility of CGRP and substance P levels as biomarkers to assess diagnosis and treatment response in patients with post-operative meningitis followed in the intensive care unit.",[578,552,29],"Meningitis",[580,581,582],"Postoperative meningitis","Calcitonin gene-related peptide","Substance P","2024-07-15",{"date":585,"type":35},"2024-07-19",{"date":587,"type":35},"2024-03-01",{"date":589,"type":21},"2025-08-30",{"name":591,"class":42},"Melike Cengiz",{"id":593,"slug":594,"hasResults":11,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":189,"sex":51,"minAge":599,"maxAge":600,"enrollmentInfo":601,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":603,"conditions":604,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":4},"100436550","a-multicenter-clinical-study-of-echocardiographic-assessment-of-right-heart-function-and-implications-of-prognosis-in-diabetes-100436550","NCT04964713","A Multicenter Clinical Study of Echocardiographic Assessment of Right Heart Function and Implications of Prognosis in Diabetes","A Multicenter Clinical Study of Echocardiographic Assessment of Right Heart Function and Implications of Prognosis in Diabetes Mellitus","Inclusion Criteria:\n\npeople with T2DM according to the WHO 2006 criteria\n\nExclusion Criteria:\n\nincluding history or symptoms of CAD valvular heart disease, rhythm disturbances cardiomyopathy congenital heart disease symptomatic heart failure pulmonary disease","35 Years","79 Years",{"count":602,"type":21},2300,"The aims of this study are to 1. Evaluate the right heart structure and function in T2DM and Prediabetes patients by speckle tracking echocardiography, and to further investigate the influence of left heart on right heart structure and function in T2DM and Prediabetes patients. 2. To explore the prognostic value of right ventricular function in T2DM patients.",[605,29],"Diabetes","2022-07-12",{"date":608,"type":35},"2022-07-13",{"date":610,"type":21},"2023-12-01",{"date":612,"type":21},"2031-12-31",{"name":614,"class":42},"Xie Mingxing",{"id":616,"slug":617,"hasResults":11,"nctId":618,"briefTitle":619,"officialTitle":619,"acronym":4,"eligibilityCriteria":620,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":219,"enrollmentInfo":621,"targetDuration":465,"studyType":54,"phases":4,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":180},"100467662","stereotactic-radiosurgery-prognosis-assessment-for-spinal-tumors-based-on-radiomics-100467662","NCT05369689","Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics","Inclusion Criteria:\n\nA diagnosis of spinal tumors for which SBRT is appropriate Karnofsky Performance Status \\>60 Life expectancy of at least 3 months No contraindication to undergoing MR imaging Age \\>18 Complete the CT MRI or PET-CT examination before and after treatment Accept stereotactic radiosurgery\n\nExclusion Criteria:\n\nSubjects unable to undergo MRI (includes non-MRI compatible material or devices and severe claustrophobia) Subjects with prior procedural intervention to the involved vertebral body that would result in artifact (kyphoplasty, screw and\u002For rod placement); minimally invasive surgery without instrumentation of the involved vertebral body and instrumentation immediately above or below the index lesion is allowed.\n\nSubjects with spinal cord compression; minimally invasive \"separation\" surgery to first resect the epidural component is allowed Pregnant or breast-feeding women Allergy to standard IV contrast agents used in MRI",{"count":622,"type":21},300,"This study aims to assess multimodal Radiomics-based prediction model for prognostic prediction in spinal tumors.",[625,626,627,29],"Stereotactic Radiosurgery","Spinal Tumor","Radiomics","2022-05-07",{"date":630,"type":35},"2022-05-11",{"date":632,"type":21},"2022-06-01",{"date":634,"type":21},"2027-06-01",{"name":636,"class":42},"Zhuang Hongqing",{"id":638,"slug":639,"hasResults":11,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":644,"targetDuration":645,"studyType":54,"phases":4,"briefSummary":646,"conditions":647,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":180},"100391505","prognostic-value-of-bnp-in-mcs---a-25-year-follow-up-study-100391505","NCT04377854","Prognostic Value of BNP in MCS - a 25 Year Follow up Study","The Prognostic Value of proBNP in Patients Supported With Durable Mechanical Circulatory Assist Devices - a 25 Year Follow up Study.","Inclusion Criteria:\n\n* All patients referred for evaluation for advanced HF treatment at the Rigshospital in Denmark\n* Age\\>18 years\n\nExclusion Criteria:\n\n* No consent",{"count":464,"type":21},"25 Years","A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy.\n\nPatients will be followed up for 25 years after inclusion.",[198,648,29,649],"Left Ventricular Assist Device","Durable Mechanical Support Device","2021-04-29",{"date":652,"type":35},"2021-05-05",{"date":654,"type":35},"2020-09-18",{"date":656,"type":21},"2045-08-01",{"name":658,"class":42},"Rigshospitalet, Denmark"]